Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2018
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancerConstance Thibault, Jean-Christophe Eymard, Alison Birtle, et al.
European Urology|May 22, 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed TomographyYohann Loriot, Matthieu Texier, Stéphane Culine, et al.
JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defectsMihaela Aldea, Laurent Lam, Emeline Orillard, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
European Urology|June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZAEmeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
JAMA Oncology|October 26, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical TrialStéphane Oudard, Raffaele Ratta, Eric Voog, et al.
European Urology Oncology|August 14, 2024
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY TrialStephane Oudard, Yohann Tran, Carole Helissey, et al.
Pageof 6